
Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB 12/26/1959
Gender: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 01/01/2017 12:34

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ERBB2 (HER2/neu) (HercepTest) with Interpretation by Immunohistochemistry, Tissue

ARUP test code 0049174

ERBB2 (HercepTest) by IHC

1+ Negative

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 19-267-150765
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 4 | Printed: 11/24/2020 1:20:20 PM
4848

This result has been reviewed and approved by [REDACTED]

INTERPRETIVE INFORMATION: HercepTest

Breast Tumors:

The result of the HercepTest by Dako (Agilent) is interpreted in a semi-quantitative manner. Test is FDA-approved for breast and gastric cancer only, and performed on formalin-fixed, paraffin-embedded tissue. Antibody clone is polyclonal and uses a proprietary detection system.

ARUP Laboratories uses the 2018 ASCO/CAP guidelines for interpretation of ERBB2 (HER2) protein expression in breast cancers fixed in formalin for 6-72 hours with a cold ischemic time of less than 1 hour. Tissue not meeting these requirements or tissue placed in decalcification solution should be interpreted with caution due to the likelihood of false negative results.

Positive cases are those with uniform, intense, complete circumferential membrane staining of more than 10 percent of invasive tumor cells (score 3+). Negative cases are defined as a) no staining observed, or incomplete membrane staining that is faint or barely perceptible and is less than or equal to 10 percent of the invasive tumor cells (score 0), or b) incomplete membrane staining that is faint or barely perceptible and is greater than 10 percent of the invasive tumor cells (score 1+). Equivocal cases are those with weak to moderate complete membrane staining observed in greater than 10 percent of tumor cells (score 2+). Other rare staining patterns may be considered equivocal. It is recommended that an Equivocal result be reflexed to another method of testing.

For more information refer to the ASCO/CAP guidelines found at www.jco.org.

Controls stained appropriately.

Percent of Cells/Circumferential	2
Intensity of Staining	Weak
Homogenous Pattern	Linear

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 19-267-150765
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 4 | Printed: 11/24/2020 1:20:20 PM
4848

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
ERBB2 (HercepTest) by IHC	19-267-150765	9/24/2019 10:54:00 AM	10/8/2019 8:09:58 AM	10/9/2019 10:42 00 AM
Percent of Cells/Circumferential	19-267-150765	9/24/2019 10:54:00 AM	10/8/2019 8:09:58 AM	10/9/2019 10:42 00 AM
Intensity of Staining	19-267-150765	9/24/2019 10:54:00 AM	10/8/2019 8:09:58 AM	10/9/2019 10:42 00 AM
Homogenous Pattern	19-267-150765	9/24/2019 10:54:00 AM	10/8/2019 8:09:58 AM	10/9/2019 10:42 00 AM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 19-267-150765
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 4 of 4 | Printed: 11/24/2020 1:20:20 PM
4848